ReviewHuman vaccines & immunotherapeutics2015
Malaria invasion ligand RH5 and its prime candidacy in blood-stage malaria vaccine design.
Review in Human vaccines & immunotherapeutics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Positive-unlabeled learning identifies vaccine candidate antigens in the malaria parasite Plasmodium falciparum.NPJ systems biology and applications · 2024Article
- Limited genetic variations of the Rh5-CyRPA-Ripr invasion complex inFrontiers in tropical diseases · 2023Article
- The Cellular and Molecular Interaction Between Erythrocytes andFrontiers in cellular and infection microbiology · 2022Review
- Erythrocyte CD55 mediates the internalization ofeLife · 2021Article
- Evaluation of Plasmodium falciparum MSP10 and its development as a serological tool for the Peruvian Amazon region.Malaria journal · 2019Article
- Review
- Article
- CRISPR/Cas9 knockouts reveal genetic interaction between strain-transcendent erythrocyte determinants ofProceedings of the National Academy of Sciences of the United States of America · 2017Article
- P113 is a merozoite surface protein that binds the N terminus of Plasmodium falciparum RH5.Nature communications · 2017Article
- Potential ofIranian journal of parasitologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
With drug resistance to available therapeutics continuing to develop against Plasmodium falciparum malaria, the development of an effective vaccine candidate remains a major research goal. Successful interruption of invasion of parasites into erythrocytes during the blood stage of infection will prevent the severe clinical symptoms and complications associated with malaria. Previously studied blood stage antigens have highlighted the hurdles that are inherent to this life-cycle stage, namely that highly immunogenic antigens are also globally diverse, resulting in protection only against the vaccine strain, or that naturally acquired immunity to blood stage antigens do not always correlate with actual protection. The blood stage antigen reticulocyte binding homolog RH5 is essential for parasite viability, has globally limited diversity, and is associated with protection from disease. Here we summarize available information on this invasion ligand and recent findings that highlight its candidacy for inclusion in a blood-stage malaria vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.